Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Operations (2023 - 2025)

CG Oncology (CGON) has disclosed Cash from Operations for 3 consecutive years, with 36200000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 75.2% year-over-year to 36200000.0, compared with a TTM value of 132300000.0 through Dec 2025, down 68.08%, and an annual FY2025 reading of 132300000.0, down 68.08% over the prior year.
  • Cash from Operations was 36200000.0 for Q4 2025 at CG Oncology, up from 38864000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 7986000.0 in Q1 2023 and bottomed at 38864000.0 in Q3 2025.
  • Average Cash from Operations over 3 years is 21391000.0, with a median of 18391000.0 recorded in 2024.
  • The sharpest move saw Cash from Operations crashed 225.72% in 2024, then decreased 12.55% in 2025.
  • Year by year, Cash from Operations stood at 14645000.0 in 2023, then tumbled by 41.09% to 20662000.0 in 2024, then plummeted by 75.2% to 36200000.0 in 2025.
  • Business Quant data shows Cash from Operations for CGON at 36200000.0 in Q4 2025, 38864000.0 in Q3 2025, and 27959000.0 in Q2 2025.